Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: a randomized controlled trial

• Published in: Microbiology and immunology 2011-11, Vol.55 (11), p.783-789
• Main Authors: Uno, Shingo, Kimachi, Kazuhiko, Kei, Junko, Miyazaki, Keiichiro, Oohama, Ayano, Nishimura, Tomohiro, Ibaragi, Kayo, Odoh, Koichi, Kudo, Yasuhiro, Kino, Yoichiro
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antibodies, Viral - blood; Female; HI antibody response; Human Experimentation; Humans; Influenza A Virus, H1N1 Subtype - immunology; Influenza Vaccines - administration & dosage; Influenza Vaccines - immunology; Japan; Male; Middle Aged; pandemic H1N1 2009 vaccine; seasonal influenza vaccine; Vaccination - methods
• ISSN: 0385-5600; 1348-0421
• DOI: 10.1111/j.1348-0421.2011.00381.x

ABSTRACT Vaccination with the non‐adjuvanted split‐virion A/California/7/2009 influenza vaccine (pandemic H1N1 2009 vaccine) began in October 2009 in Japan. The present study was designed to assess the effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the pandemic H1N1 2009 vaccine in healthy adult volunteers. One hundred and seventeen participants aged 22 to 62 were randomly assigned to two study groups. In Group 1 (the priming group), participants were first vaccinated with the seasonal trivalent influenza vaccine followed by two separate one‐dose vaccinations of the pandemic H1N1 2009 vaccine, whereas in Group 2 (the non‐priming group), the participants were first vaccinated with one dose of the pandemic H1N1 2009 vaccine, followed by simultaneous vaccination of the seasonal trivalent vaccine and the second dose of the pandemic H1N1 2009 vaccine. The participants in Group 2 had a seroprotection rate (SPR) of 79.7% and a seroconversion rate (SCR) of 79.7% in the hemagglutination‐inhibition test after the first dose of the pandemic H1N1 2009 vaccine, indicating that the pandemic H1N1 2009 vaccine is sufficiently immunogenic. On the other hand, the participants of Group 1 had a significantly weaker antibody response, with a SPR of 60.8% and a SCR of 58.5%. These results indicate that prior vaccination with the seasonal trivalent influenza vaccine inhibits the antibody response to the pandemic H1N1 2009 vaccine. Therefore, the pandemic H1N1 2009 vaccine should be administered prior to vaccination with the seasonal trivalent influenza vaccine.